Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(0)
# 4250
Out of 5,240 analysts
26
Total ratings
31.82%
Success rate
-8.74%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Cabaletta Bio | Downgrades: In-Line | 15 6 | 2.21 | 171.49% | 2 | Dec 20, 2024 | |
argenx | Maintains: Outperform | 675 706 | 665.84 | 6.03% | 4 | Nov 21, 2024 | |
Sarepta Therapeutics | Maintains: Outperform | 179 170 | 118.71 | 43.21% | 9 | Nov 7, 2024 | |
Jasper Therapeutics | Maintains: Outperform | 65 65 | 5.87 | 1007.33% | 2 | Aug 26, 2024 | |
Foghorn Therapeutics | Initiates Coverage On: Outperform | 20 | 4.2 | 376.19% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 201 206 | 142.06 | 45.01% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 62 66 | 43.33 | 52.32% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 22 | 2.5 | 780% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 20 10 | 3.75 | 166.67% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 159 165 | 175.46 | -5.96% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 54 60 | 12.85 | 366.93% | 1 | Oct 5, 2022 |